Eli Lilly
LLY · NYSE · Healthcare
$1,150.99
$13.70 (-1.19%) today
Market Cap
$1.03T
24h Volume
$2.5B
P/E Ratio
38.6
52w High
$1,280.34
52w Low
$710.11
Est. AI Revenue
12%
7-Day Sparkline (Static)
Company facts
Performance
About Eli Lilly
Eli Lilly is one of the world's largest pharmaceutical companies. It makes money selling prescription drugs, led by its GLP-1 medicines for diabetes and weight loss, across global markets.
AI is now part of what it builds, not just how it works. It trains its own foundation models for biology and chemistry on LillyPod, an in-house AI supercomputer, runs a co-innovation lab with NVIDIA aimed at frontier models for drug discovery, and offers those models to smaller biotechs through TuneLab, a platform that lets partners use them without exposing their own data.
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly trades on the NYSE and employs about 50,000 people.
Eli Lilly in the AI buildout
Eli Lilly sits in the AI Healthcare and Foundation Models layers of the buildout. It is unusual among large pharma in training its own biology and chemistry foundation models, running the supercomputer they are trained on, and putting them in outside hands through TuneLab rather than keeping them internal. Those tools could compress the long timelines of drug development. The value driver is still drug demand, above all its GLP-1 franchise, so AI is an accelerant for a pharma giant rather than its engine.
LLY is tracked in AI Healthcare and Foundation Models, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
LLY trades at $1,150.99, 77% of the way up its 52-week range of $710.11 to $1,280.34.
Market cap
Market capitalization is $1.03T, with an AI Exposure Score of 10 out of 100.
Valuation vs peers
Its P/E ratio of 38.6 is above the AI Healthcare category median of 29.6.
Next earnings
Eli Lilly is next expected to report earnings on October 29, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Eli Lilly do?
Eli Lilly sells prescription drugs globally, led by its GLP-1 medicines for diabetes and weight loss. It applies AI across drug discovery, clinical trials, and manufacturing.
How is Eli Lilly exposed to AI?
As an adopter. AI may speed its pipeline and it has partnered with AI drug discovery firms, but drug demand drives the business. Supercycle rates it an AI Exposure Score of 10 out of 100.
What are Eli Lilly's main AI efforts?
An AI drug discovery platform, clinical trial optimization tools, manufacturing AI for scaling production, and precision medicine machine learning for matching treatments to patients.
Is LLY a pure play AI stock?
No. Eli Lilly is a pharmaceutical company whose value rides drug franchises like GLP-1s. AI supports the pipeline, and its AI Exposure Score of 10 out of 100 reflects that supporting role.
Where is Eli Lilly based and who leads it?
Eli Lilly is headquartered in Indianapolis, Indiana, and is led by CEO David Ricks. The company was founded in 1876 and employs about 50,000 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.